Long-term safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: 5-year results from a phase 2b study and its open-label extension

Sponsored by UCB Pharma

Feb 01, 2024 9:00 am

Click to download or view mobile version

#navpanes=0&scrollbar=0

Presentation

X. Baraliakos

Xenofon Baraliakos discusses the poster.

Author(s):

Atul Deodhar, Victoria Navarro-Compán, Denis Poddubnyy, Lianne S. Gensler, Sofia Ramiro, Tetsuya Tomita, Helena Marzo‑Ortega, Carmen Fleurinck, Thomas Vaux, Ute Massow, Désirée van der Heijde, Xenofon Baraliakos (narrating author)

Abstract or description:

This study aimed to report the long-term safety and efficacy of bimekizumab (BKZ) in patients with active ankylosing spondylitis (AS) up to 5 years of treatment in the phase 2b study BE AGILE and its open-label extension (OLE).

More Virtual Posters

Novartis November Poster

A US Patient Perspective on the Diagnosis and Burden of AxSpA

AbbVie Poster (Sept 2024)

Safety of a JAKi Across 15,000 Patient-Years of Data

Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Achievement of Minimal Disease Activity and Remission: Up to 2-Year Results from Two Phase 3 Studies

UCB Eular Poster

Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Studies

Presentation

X. Baraliakos

Xenofon Baraliakos discusses the poster.

Author(s):

Atul Deodhar, Victoria Navarro-Compán, Denis Poddubnyy, Lianne S. Gensler, Sofia Ramiro, Tetsuya Tomita, Helena Marzo‑Ortega, Carmen Fleurinck, Thomas Vaux, Ute Massow, Désirée van der Heijde, Xenofon Baraliakos (narrating author)

Abstract or description:

This study aimed to report the long-term safety and efficacy of bimekizumab (BKZ) in patients with active ankylosing spondylitis (AS) up to 5 years of treatment in the phase 2b study BE AGILE and its open-label extension (OLE).